Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in hypereosinophilic syndrome
NCT02130882Phase 3Unknown
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2014
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benralizumab in hypereosinophilic syndrome (HES), sponsored by National Institute of Allergy and Infectious Diseases. Status: unknown.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT02130882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130882.